Read + Share
Camidge DR. Lorlatinib Should Not be Considered as the Preferred First-Line Option in
Patients With Advanced ALK Rearranged NSCLC. J Thorac Oncol 2021;16:528-531.
PMID: 33781443
|
 |
|
Camidge DR. Lorlatinib Should Not be Considered as the Preferred First-Line Option in
Patients With Advanced ALK Rearranged NSCLC. J Thorac Oncol 2021;16:528-531.
PMID: 33781443
|
|
|
|